How do you treat bleeding disorders with desmopressin?

Postgraduate Medical Journal

Volumn 83, Issue 977, 2007, Pages 159-163

  Özgönenel, Bülent ^a,b   Rajpurkar, Madhvi ^b   Lusher, Jeanne M ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; DESMOPRESSIN ACETATE; VON WILLEBRAND FACTOR;

ARTERY THROMBOSIS; BLEEDING DISORDER; DRUG MECHANISM; EMERGENCY WARD; EPISTAXIS; FLUSHING; HEADACHE; HEMOPHILIA A; HUMAN; HYPONATREMIA; NURSE PRACTITIONER; PATIENT CARE; PRIMARY MEDICAL CARE; REPEATED DRUG DOSE; REVIEW; SEIZURE; SELF EVALUATION; SIDE EFFECT; TACHYCARDIA; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE;

DEAMINO ARGININE VASOPRESSIN; DRUG ADMINISTRATION ROUTES; HEMORRHAGIC DISORDERS; HEMOSTATICS; HUMANS; VON WILLEBRAND FACTOR;

EID: 33947524896     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.052118     Document Type: Review

References (25)

1. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245-53.
2. Warrier AI, Lusher JM. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease. J Pediatr 1983;102:228-33.
3. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997;90:2515-21.
4. Ginsburg D. von Willebrand disease. In: Beutler E, Coller BS, Lichtman MA, Kipps TJ, eds. Williams hematology.6th edn. Philadelphia: McGraw-Hill, 2001:1813-28.
5. Castaman G, Federici AB, Rodeghiero F, et al. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003;88:94-108.
6. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005;106:11-17.
7. Thibonnier M. Vasopressin agonists and antagonists. Harm Res 1990;34:124-8.
8. Scott H. Use of desmopressin, antifibrinolytics, and conjugated estrogens in hemostasis. In: Goodnight J, Hathaway WE, eds. Disorders of hemostasis & thrombosis:a clinical guide. 2nd edn. USA: McGraw-Hill, 2001:528-42.
9. Lusher JM. Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease. Haemostasis 1994;24:276-84.
10. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004;351:683-94.
11. Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004;103:2032-8.
12. Kaufman RJ, Antonarakis SE. Structure, biology, and genetics of factor VIII. In: Hoffman R, Edward J, Benz J, Shattil SJ, Furie B, Cohen HJ, et al, eds. Hematology:basic principles and practice.3rd edn. Philadelphia: Churchill Livingstone, 2000:1850-68.
13. Kujovich JL. von Willebrand's disease and menorrhagia: prevalence, diagnosis, and management. Am J Hematol 2005;79:220-8.
14. Leissinger C, Becton D, Cornell C Jr, et al. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001;7:258-66.
15. Amesse LS, Pfaff-Amesse T, Leonardi R, et al. Oral contraceptives and DDAVP nasal spray: patterns of use in managing vWD-associated menorrhagia: a single-institution study. J Pediatr Hematol Oncol 2005;27:357-63.
16. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996;76:692-6.
17. Lee CA, Abdul-Kadir R. von Willebrand disease and women's health. Semin Hematol 2005;42:42-8.
18. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005;130:3-10.
19. Franchini M, Gandini G, Manzato F, et al. Evaluation of the PFA-100 system for monitoring desmopressin therapy in patients with type 1 von Willebrand's disease. Haematologica 2002;87:670.
20. Das P, Carcao M, Hitzler J. DDAVP-induced hyponatremia in young children. J Pediatr Hematol Oncol 2005;27:330-2.
21. Mannucci PM, Lusher JM. Desmopressin and thrombosis. Lancet 1989;2:675-6.
22. Girolami A, Tezza F, Scapin M, et al. Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature. J Thromb Thrombolysis 2006;21:175-8.
23. Overman M, Brass E. Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration. Thromb Haemost 2004;92:886-7.
24. McKeown LP, Connaqhan G, Wilson O, et al. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease. Am J Hematol 1996;51:158-63.
25. Ehl S, Severin T, Sutor AH. DDAVP (desmopressin; 1-deamino-cys-8-D-arginine-vasopressin) treatment in children with haemophilia B. Br J Haematol 2000;111:1260-2.